A carregar...
A Phase Ib Study of Single‐Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
LESSONS LEARNED: Although this study of idelalisib in patients with PDAC was limited in size and duration because of early termination, idelalisib exposure resulted in an overall safety profile consistent with studies in hematological malignancies, except that the incidences of diarrhea and colitis...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7648342/ https://ncbi.nlm.nih.gov/pubmed/32356383 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0321 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|